AstraZeneca: Enhertu (fam-Trastuzumab Deruxtecan-Nxki) Approved in the US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients With Metastatic HER2-Positive Solid Tumors
April 06, 2024
April 06, 2024
WILMINGTON, Delaware, April 6 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca and Daiichi Sankyo's ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
This indication is approved under accelerated approval . . .
AstraZeneca and Daiichi Sankyo's ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
This indication is approved under accelerated approval . . .